18F-FDG-PET/CT in the assessment of pancreatic cancer: Is the contrast or a better-designed trial needed?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 4, 2011, Pages 613-615

  Nguyen, Nam Q ^a   Bartholomeusz, Dylan F ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER INVASION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; EDITORIAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; MORBIDITY; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; TUMOR RECURRENCE;

EID: 79952852750     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06625.x     Document Type: Editorial

References (11)

1. Michl P, Pauls S, Gress TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006; 20: 227-51.
2. Pakzad F, Groves AM, Ell PJ. The role of positron emission tomography in the management of pancreatic cancer. Semin. Nucl. Med. 2006; 36: 248-56.
3. Serrano OK, Chaudhry MA, Leach SD. The role of PET scanning in pancreatic cancer. Adv. Surg. 2010; 44: 313-25.
4. Ell PJ. PET/CT in oncology: a major technology for cancer care. Chang Gung Med. J. 2005; 28: 274-83.
5. Heinrich S, Goerres GW, Schafer M etal. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann. Surg. 2005; 242: 235-43.
6. Tang S, Huang G, Liu J etal. Usefulness of (18)F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur. J. Radiol. 2009; (in press).
7. Kauhanen SP, Komar G, Seppanen MP etal. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann. Surg. 2009; 250: 957-63.
8. Casneuf V, Delrue L, Kelles A etal. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta. Gastroenterol. Belg. 2007; 70: 331-8.
9. Schick V, Franzius C, Beyna T etal. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 1775-85.
10. Strobel K, Heinrich S, Bhure U etal. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J. Nucl. Med. 2008; 49: 1408-13.
11. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: A prospective study. J. Gastroenterol. Hepatol. 2011; 26: 657-62.